Efficacy of an EGFR-specific peptide against EGFR-dependent cancer cell lines and tumor xenografts

Neoplasia (United States)

Volumn 16, Issue 2, 2014, Pages 105-114

  Ahsa, Aarif ^a   Ramanand, Susmita G ^a   Bergin, Ingrid L ^a   Zha, Lilli ^a   Whitehead, Christopher E ^a   Rehemtulla, Alnawaz ^a   Ray, Dipankar ^a   Pratt, William B ^a   Lawrence, Theodore S ^a   Nyati, Mukesh K ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CETUXIMAB; CISPLATIN; DISRUPTIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; UNCLASSIFIED DRUG; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR (768-775); PEPTIDE FRAGMENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL SURVIVAL; CLONOGENESIS; CONTROLLED STUDY; DIMERIZATION; DRUG EFFICACY; FEMALE; HISTOLOGY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; TOXICITY TESTING; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CARCINOMA, SQUAMOUS CELL; CHO CELL LINE; CRICETULUS; DRUG EFFECTS; DRUG SCREENING; HEAD AND NECK NEOPLASMS; METABOLISM; NUDE MOUSE; PATHOLOGY; TOXICITY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL SURVIVAL; CHO CELLS; CISPLATIN; CRICETULUS; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MICE, INBRED C57BL; MICE, NUDE; PEPTIDE FRAGMENTS; PROTEOLYSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84900425561     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.14182     Document Type: Article

References (50)

1. Luo J, Solimini NL, and Elledge SJ (2009). Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 136, 823-837.
2. Yarden Y and Sliwkowski MX (2001). Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2, 127-137.
3. Thatcher N, Chang A, Parikh P, Pereira JR, Ciuleanu T, von Pawel J, Thongprasert S, Tan EH, Pemberton K, Archer V, et al. (2005). Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366, 1527-1537.
4. Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG, and Halmos B (2005). EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352, 786-792.
5. Weihua Z, Tsan R, Huang WC, Wu Q, Chiu CH, Fidler IJ, and Hung MC (2008). Survival of cancer cells is maintained by EGFR independent of its kinase activity. Cancer Cell 13, 385-393.
6. Ahsan A, Hiniker SM, Ramanand SG, Nyati S, Hegde A, Helman A, Menawat R, Bhojani MS, Lawrence TS, and Nyati MK (2010). Role of epidermal growth factor receptor degradation in cisplatin-induced cytotoxicity in head and neck cancer. Cancer Res 70, 2862-2869.
7. Argiris A, Duffy AG, Kummar S, Simone NL, Arai Y, Kim SW, Rudy SF, Kannabiran VR, Yang X, Jang M, et al. (2011). Early tumor progression associated with enhanced EGFR signaling with bortezomib, cetuximab, and radiotherapy for head and neck cancer. Clin Cancer Res 17, 5755-5764.
8. Feng FY, Varambally S, Tomlins SA, Chun PY, Lopez CA, Li X, Davis MA, Chinnaiyan AM, Lawrence TS, and Nyati MK (2007). Role of epidermal growth factor receptor degradation in gemcitabine-mediated cytotoxicity. Oncogene 26, 3431-3439.
9. Ray D, Ahsan A, Helman A, Chen G, Hegde A, Gurjar SR, Zhao L, Kiyokawa H, Beer DG, Lawrence TS, et al. (2011). Regulation of EGFR protein stability by the HECT-type ubiquitin ligase SMURF2. Neoplasia 13, 570-578.
10. Neckers L, Mollapour M, and Tsutsumi S (2009). The complex dance of the molecular chaperone Hsp90. Trends Biochem Sci 34, 223-226.
11. Workman P (2004). Altered states: selectively drugging the Hsp90 cancer chaperone. Trends Mol Med 10, 47-51.
12. Xu W, Mimnaugh E, Rosser MFN, Nicchitta C, Marcu M, Yarden Y, and Neckers L (2001). Sensitivity of mature ErbB2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90. J Biol Chem 276, 3702-3708.
13. Citri A, Alroy I, Lavi S, Rubin C, Xu W, Grammatikakis N, Patterson C, Neckers L, Fry DW, and Yarden Y (2002). Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy. EMBO J 21, 2407-2417.
14. Ahsan A, Ramanand SG, Whitehead C, Hiniker SM, Rehemtulla A, Pratt WB, Jolly S, Gouveia C, Truong K, Van Waes C, et al. (2012). Wild-type EGFR is stabilized by direct interaction with HSP90 in cancer cells and tumors. Neoplasia 14, 670-677.
15. Yang S, Qu S, Perez-Tores M, Sawai A, Rosen N, Solit DB, and Arteaga CL (2006). Association with HSP90 inhibits Cbl-mediated down-regulation of mutant epidermal growth factor receptors. Cancer Res 66, 6990-6997.
16. Shimamura T, Li D, Ji H, Haringsma HJ, Liniker E, Borgman CL, Lowell AM, Minami Y, McNamara K, Perera SA, et al. (2008). Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance. Cancer Res 68, 5827-5838.
17. Lavictoire SJ, Parolin DA, Klimowicz AC, Kelly JF, and Lorimer IA (2003). Interaction of Hsp90 with the nascent form of the mutant epidermal growth factor receptor EGFRvIII. J Biol Chem 278, 5292-5299.
18. Pratt WB, Morishima Y, and Osawa Y (2008). The Hsp90 chaperone machinery regulates signaling by modulating ligand binding clefts. J Biol Chem 283, 22885-22889.
19. Citri A, Gan J, Mosesson Y, Vereb G, Szollosi J, and Yarden Y (2004). Hsp90 restrains ErbB-2/HER2 signalling by limiting heterodimer formation. EMBO Rep 5, 1165-1170.
20. Tikhomirov O and Carpenter G (2003). Identification of ErbB-2 kinase domain motifs required for geldanamycin-induced degradation. Cancer Res 63, 39-43.
21. Citri A, Harari D, Shohat G, Ramakrishnan P, Gan J, Lavi S, Eisenstein M, Kimchi A, Wallach D, Pietrokovski S, et al. (2006). Hsp90 recognizes a common surface on client kinases. J Biol Chem 281, 14361-14369.
22. Ahsan A, Ray D, Ramanand SG, Hegde A, Whitehead C, Rehemtulla A, Morishima Y, Pratt WB, Osawa Y, Lawrence TS, et al. (2013). Destabilization of the epidermal growth factor receptor (EGFR) by a peptide that inhibits EGFR binding to heat shock protein 90 and receptor dimerization. J Biol Chem 288, 26879-26886.
23. Schlessinger J (2000). Cell signaling by receptor tyrosine kinases. Cell 103, 211-225.
24. Shan Y, Eastwood MP, Zhang X, Kim ET, Arkhipov A, Dror RO, Jumper J, Kuriyan J, and Shaw DE (2012). Oncogenic mutations counteract intrinsic disorder in the EGFR kinase and promote receptor dimerization. Cell 149, 860-870.
25. Huse M and Kuriyan J (2002). The conformational plasticity of protein kinases. Cell 109, 275-282.
26. Futaki S, Suzuki T, Ohashi W, Yagami T, Tanaka S, Ueda K, and Sugiura Y (2001). Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J Biol Chem 276, 5836-5840.
27. Lawrence TS (1988). Reduction of doxorubicin cytotoxicity by ouabain: correlation with topoisomerase-induced DNA strand breakage in human and hamster cells. Cancer Res 48, 725-730.
28. Kong M and Yan J (2011). Modeling and testing treated tumor growth using cubic smoothing splines. Biom J 53, 595-613.
29. Nimmanapalli R, O'Bryan E, and Bhalla K (2001). Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts. Cancer Res 61, 1799-1804.
30. Xiao Y, Gao X, Maragh S, Telford WG, and Tona A (2009). Cell lines as candidate reference materials for quality control of ERBB2 amplification and expression assays in breast cancer. Clin Chem 55, 1307-1315.
31. Diermeier S, Horváth G, Knuechel-Clarke R, Hofstaedter F, Szöllosi J, and Brockhoff G (2005). Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation. Exp Cell Res 304, 604-619.
32. Modjtahedi H and Dean C (1994). The receptor for EGF and its ligands - expression, prognostic value and target for therapy in cancer (review). Int J Oncol 4, 277-296.
33. Kopp R, Rothbauer E, Ruge M, Arnholdt H, Spranger J, Muders M, Pfeiffer DG, Schildberg FW, and Pfeiffer A (2003). Clinical implications of the EGF receptor/ligand system for tumor progression and survival in gastrointestinal carcinomas: evidence for new therapeutic options. Recent Results Cancer Res 162, 115-132.
34. Whitesell L and Lindquist SL (2005). HSP90 and the chaperoning of cancer. Nat Rev Cancer 5, 761-772.
35. Zhang X, Gureasko J, Shen K, Cole PA, and Kuriyan J (2006). An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 125, 1137-1149.
36. Messersmith W, Oppenheimer D, Peralba J, Sebastiani V, Amador M, Jimeno A, Embuscado E, Hidalgo M, and Iacobuzio-Donahue C (2005). Assessment of epidermal growth factor receptor (EGFR) signaling in paired colorectal cancer and normal colon tissue samples using computer-aided immunohistochemical analysis. Cancer Biol Ther 4, 1381-1386.
37. Aquino G, Pannone G, Santoro A, Liguori G, Franco R, Serpico R, Florio G, De Rosa A, Mattoni M, Cozza V, et al. (2012). pEGFR-Tyr 845 expression as prognostic factors in oral squamous cell carcinoma: a tissue-microarray study with clinic-pathological correlations. Cancer Biol Ther 13, 967-977.
38. Socinski MA, Goldman J, El-Hariry I, Koczywas M, Vukovic V, Horn L, Paschold E, Salgia R, West H, Sequist LV, et al. (2013). A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clin Cancer Res 19, 3068-3077.
39. Feng FY, Kim HM, Lyden TH, Haxer MJ, Feng M, Worden FP, Chepeha DB, and Eisbruch A (2007). Intensity-modulated radiotherapy of head and neck cancer aiming to reduce dysphagia: early dose-effect relationships for the swallowing structures. Int J Radiat Oncol Biol Phys 68, 1289-1298.
40. Ahsan A, Hiniker SM, Davis MA, Lawrence TS, and Nyati MK (2009). Role of cell cycle in epidermal growth factor receptor inhibitor-mediated radiosensitization. Cancer Res 69, 5108-5114.
41. Burtness B (2005). The role of cetuximab in the treatment of squamous cell cancer of the head and neck. Expert Opin Biol Ther 5, 1085-1093.
42. Kirisits A, Pils D, and Krainer M (2007). Epidermal growth factor receptor degradation: an alternative view of oncogenic pathways. Int J Biochem Cell Biol 39, 2173-2182.
43. Kim WY, Oh SH, Woo JK, Hong WK, and Lee HY (2009). Targeting heat shock protein 90 overrides the resistance of lung cancer cells by blocking radiation-induced stabilization of hypoxia-inducible factor-1α. Cancer Res 69, 1624-1632.
44. Bisht KS, Bradbury CM, Mattson D, Kaushal A, Sowers A, Markovina S, Ortiz KL, Sieck LK, Isaacs JS, Brechbiel MW, et al. (2003). Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity. Cancer Res 63, 8984-8995.
45. Sharp S and Workman P (2006). Inhibitors of the HSP90 molecular chaperone: current status. Adv Cancer Res 95, 323-348.
46. Pacey S, Wilson RH, Walton M, Eatock MM, Hardcastle A, Zetterlund A, Arkenau HT, Moreno-Farre J, Banerji U, Roels B, et al. (2011). A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors. Clin Cancer Res 17, 1561-1570.
47. LaBelle JL, Katz SG, Bird GH, Gavathiotis E, Stewart ML, Lawrence C, Fisher JK, Godes M, Pitter K, Kung AL, et al. (2012). A stapled BIM peptide overcomes apoptotic resistance in hematologic cancers. J Clin Invest 122, 2018-2031.
48. Liu M, Li C, Pazgier M, Li C, Mao Y, Lv Y, Gu B, Wei G, Yuan W, Zhan C, et al. (2010). D-peptide inhibitors of the p53-MDM2 interaction for targeted molecular therapy of malignant neoplasms. Proc Natl Acad Sci USA 107, 14321-14326.
49. Gao C, Dimitrov T, Yong KJ, Tatetsu H, Jeong HW, Luo HR, Bradner JE, Tenen DG, and Chai L (2013). Targeting transcription factor SALL4 in acute myeloid leukemia by interrupting its interaction with an epigenetic complex. Blood 121, 1413-1421.
50. Yong KJ, Gao C, Lim JS, Yan B, Yang H, Dimitrov T, Kawasaki A, Ong CW, Wong KF, Lee S, et al. (2013). Oncofetal gene SALL4 in aggressive hepatocellular carcinoma. N Engl J Med 368, 2266-2276.